We present here the results of developing a complex method for the differential diagnosis of malignant tumors of the uterine adnexa which was used as the basis for the “Risk Ovarian Cancer v.2.2” computer system. Measures of the sensitivity and specificity of this system and the potential for its use are presented.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Alekseeva, M. L., Gusarova, E. V., Mullabaeva, S. M., and Ponkratova, T. S., “Oncological markers and various aspects of their clinical and diagnostic use (literature review),” Probl. Reprodukts., No. 3, 65-79 (2005).
Borisova, E. A., Pashov, A. I., and Bulanov, M. N., “Current state of the problem of the differential diagnosis of ovarian tumors,” Sib. Med. Obozr., No. 6, 14-19 (2014).
Zhordania, K. I., “Serous tumor of the ovary or serous tumor of the fallopian tube?,” Onkoginekologiya, No. 3, 4-9 (2012).
Nikogosyan, S. O., Kadagidze, Z. G., Shelepova, V. M., and Kuznetsov, V. V., “Current methods in the immunodiagnosis of malignant neoplasms of the ovaries,” Onkoginekologiya, No 3, 49-54 (2014).
Lu, K. H., Skates, S., Hernandez, M. A., Bedi, D., Bevers, T., Leeds, L., Moore, R., Granai, C., Harris, S., Newland, W., Adeyinka, O., Geffen, J., Deavers, M. T., Sun, C. C., Horick, N., Fritsche, H., and Bast, R. C., Jr., “A 2-stage ovarian cancer screening strategy using the Risk of Ovarian Cancer Algorithm (ROCA) identifies early-stage incident cancers and demonstrates high positive predictive value,” Cancer, 119, No. 19, 3454-3461 (2013).
Sergeeva, N. S. and Marshutina N. V., “Tumor-associated markers in screening programs for active detection of ovarian tumors: the reality, problems, and perspectives,” Praktichesk. Onkol., 11, No. 2, 110-119 (2010).
Starinskii, V. V., Sergeeva, N. S., Marshutina, N. V., and Korneeva, I. A., “Problems of the early diagnosis and screening for ovarian cancer: the reality and potential,” Onkol. Zh. im. P. A. Gertsena, No. 1, 56-62 (2013).
Braga, F., Ferraro, S., Mozzi, R., and Panteghini, M., “The importance of individual biology in the clinical use of serum bio-markers for ovarian cancer,” Clin. Chem. Lab. Med., 52, No. 11, 1625-1631 (2014).
Park, Y., Kim, Y., Young Lee, E., Jong-Han Lee, and Hyon-Suk Kim, “Reference ranges for HE4 and CA125 in a large Asian population by automated assays and diagnostic performances for ovarian cancer,” Int. J. Cancer, 130, No. 5, 1136-1144 (2012).
Anastasi, E., Granato, T., Falzarano, R., Storelli, P., Ticino, A., Frati, L., and Porpora, M. G., “The use of HE4, CA125 and CA72-4 biomarkers for differential diagnosis between ovarian endometrioma and epithelial ovarian cancer,” J. Ovarian Res., No. 6, 44 (2013).
Bulanov, M. N., Ultrasound Gynecology. A Course of Lectures in Three Volumes, Vol. II [in Russian], Vidar-M, Moscow (2010).
Moore, R. G., McMeekin, D. S., Brown, A. K., DiSilvestro, P., Miller, M. C., Allard, W. J., Gajewski, W., Kurman, R., Bast R. C. Jr., and Skates, S. J., “A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass,” Gynecol. Oncol., 112, No. 1, 40-46 (2008).
Author information
Authors and Affiliations
Corresponding author
Additional information
Translated from Meditsinskaya Tekhnika, Vol. 51, No. 5, Sep.-Oct., 2017, pp. 49-52.
Rights and permissions
About this article
Cite this article
Narkevich, A.N., Borisova, E.A. & Makarenko, T.A. A System for the Differential Diagnosis of Malignant Tumors of the Adnexa of the Uterus Based on a Neural Network. Biomed Eng 51, 368–372 (2018). https://doi.org/10.1007/s10527-018-9750-y
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10527-018-9750-y